Research programme: scavenger receptor B1 modulators - KineMedAlternative Names: SR-B1 therapeutics
Latest Information Update: 16 Jul 2016
At a glance
- Originator KineMed
- Mechanism of Action SCARB1 protein modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Atherosclerosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Atherosclerosis in USA
- 15 May 2007 Preclinical trials in Atherosclerosis in USA (unspecified route)